德巴金和喜保宁哪个副作用大？

Compared with Vigabatrin (vigabatrin), Depakin (sodium valproate) has greater side effects and can cause blood and lymphatic system abnormalities, such as anemia and thrombocytopenia; nervous system abnormalities, such as tremor, extrapyramidal disorder, stupor, drowsiness, convulsions, memory impairment, and headache.

Ear and labyrinth abnormalities, common quadratonia; gastrointestinal system abnormalities such as nausea, vomiting, epigastric pain, diarrhea; skin and subcutaneous tissue abnormalities, common hypersensitivity reactions, transient and/or dose-related alopecia, nail and nail bed diseases.

These side effects often occur at the beginning of treatment and do not require stopping treatment. These symptoms usually disappear within a few days and generally do not require special treatment.

Vigabatrin

The exact mechanism of the anti-epileptic effect is not yet clear, but it may be the result of an irreversible inhibitor of gamma-aminobutyric acid aminotransferase (GABA-T), leading to an increase in GABA levels in the central nervous system by inhibiting GABA-T.

Vigabatrin (VGB) is a structural analog of gamma-aminobutyric acid (GABA), which irreversibly inhibits GABA-aminotransferase (GABA-T) and increases brain levels of GABA. Clinically, vigabatrin is used in combination with other anti-epileptic drugs to treat refractory partial epilepsy with or without subsequent systemic seizures.

Debakin

The anti-epileptic activity may be related to increasing the concentration of γ-aminobutyric acid in the brain and can be used to treat generalized epilepsy and partial epilepsy, such as partial seizures, with or without generalized seizures. It is also used to treat manic episodes associated with bipolar disorder.

Vigabatrin

Common side effects are fatigue, drowsiness, headache, dizziness, confusion, visual impairment, and depression. Most of the side effects in adult patients are related to the central nervous system, such as sedation, drowsiness, fatigue, and inability to concentrate. Children are more likely to experience excitement or agitation.

VGB is being evaluated for treatment of infantile spasms (IS) and refractory complex partial epilepsy (CPS). After about 2 weeks of treatment, the spasms stopped and the response was rapid. Cessation of spasticity has been achieved in patients with symptomatic tuberous sclerosis (TS) and others. Comparisons were made with adrenocorticotropin, and patients with refractory CPS also responded.

Vigabatrin is secreted in breast milk. Breastfeeding is not allowed during treatment with vigabatrin. The visual impairment caused by vigabatrin will affect driving ability and mechanical operation. Patients who drive, operate machinery or perform hazardous work should pay special attention.

Recommended related articles: